 |
1 Disease |  |
12 Trials |
|
12 Trials |  |
86 News |  |
| «12 |
- ||| ifebemtinib (IN10018) / InxMed
Trial completion, Metastases: A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer (clinicaltrials.gov) - Nov 24, 2015
P1, N=96, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed
- || ifebemtinib (IN10018) / InxMed
Enrollment closed, Metastases: A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer (clinicaltrials.gov) - Aug 12, 2015
P1, N=90, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | ifebemtinib (IN10018) / InxMed
Trial completion, Metastases: A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer (clinicaltrials.gov) - Aug 7, 2014
P1, N=21, Completed, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ifebemtinib (IN10018) / InxMed
Enrollment closed, Metastases: A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer (clinicaltrials.gov) - Jun 26, 2014
P1, N=20, Active, not recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ifebemtinib (IN10018) / InxMed
Enrollment change, Metastases: A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer (clinicaltrials.gov) - Mar 4, 2014
P1, N=20, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting N=30 --> 20
- ifebemtinib (IN10018) / InxMed
Enrollment open, Metastases: A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer (clinicaltrials.gov) - Jul 23, 2013
P1, N=20, Recruiting, Sponsor: Boehringer Ingelheim
N=30 --> 20 Not yet recruiting --> Recruiting
- | ifebemtinib (IN10018) / InxMed
New P1 trial, Metastases: A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer (clinicaltrials.gov) - Jul 21, 2013
P1, N=20, Recruiting, Sponsor: Boehringer Ingelheim